Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Although cyclophosphamide (CFA) remain the cornerstone for treatment of patients with severe manifestations of systemic autoimmune diseases, the knowledge about the effect of CFA on circulating cell populations in these diseases is limited.
Objectives: To investigate the effect of CFA administration on circulating immune cell subpopulations in patients with vasculitis and autoimmune systemic diseases.
Methods: We analysed major immune cell populations in peripheral blood (PB) from 13 patients (vasculitis n=7; autoimmune systemic diseases n=6). Paired samples from each patient were analysed before CFA administration, and after one and six months’ follow-up. Using 6-colour flow cytometer (BD FACSCanto II) we characterized T lymphocytes (CD3, CD4, CD8, CD25, CD127, HLA-DR), B lymphocytes (CD19, CD20, CD27, HLA-DR), NK cells (CD3, CD16, CD56, CD69), neutrophils (CD15, CD11b, CD16, CD54, CD62L, CD64), and monocytes (CD11b, CD14, CD16, CD64, HLA-DR). Statistics was done by software GraphPad Prism.
Results: After single dose of CFA, the percentage of CD69+ NK cells increased and CD4+/CD8+ ratio decreased compared with their percentage before administration (P=0.01; P=0.03, respectively). After six months of CFA administration, decreased percentage of activation marker HLA-DR on CD4+ cells (P=0.004), decreased percentage of CD19+ B cells (P=0.04) and increased percentage of activation marker CD69 on NK cells (P=0.004) was observed comparing with paired samples obtained before CFA therapy. Different patterns were observed in subgroups of patients with vasculitis and autoimmune systemic diseases. Clinical evaluation of treatment response and observed changes in immune cell populations in individual patients is ongoing.
Conclusion: In our patients, CFA therapy resulted in changes of activation markers on CD4+, CD8+, B and NK cells, as well as neutrophils. Further investigation of selected markers may lead to identification of new biomarkers for prediction of the treatment effectiveness.
Acknowledgement: MZ CR VES15-28659A, IGA_LF_2017_009
To cite this abstract in AMA style:Skácelová M, Gabčová G, Horak P, Mikulková Z, Mrázek F, Kriegová E, Smržová A. Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cyclophosphamide-treatment-modulates-circulating-cell-populations-in-patients-with-vasculitis-and-autoimmune-systemic-diseases/. Accessed July 10, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/cyclophosphamide-treatment-modulates-circulating-cell-populations-in-patients-with-vasculitis-and-autoimmune-systemic-diseases/